← Leaderboards
Thomas D Marcotte
Systems Technology, Inc.
$6,515,268
Attributed
$7,702,318
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $890.5K · FY2005–19$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$7,702,318 · 7
By mechanism
R01$5,058,716 · 2
R42$1,652,114 · 2
R34$682,650 · 1
R41$224,953 · 1
M01$83,885 · 1
Top collaborators
- Joan M. Severson4 shared
- Barth Lance Wilsey2 shared
Most similar at Systems Technology, Inc.
Same institution · by research overlap
- R. Wade Allen$1,699,132
- Peter Newman Rosen$52,183
- Theodore J. Rosenthal$352,150
- George D. Park$400,493
Others in their field
Top investigators on “Performance”
- Jeffrey P Krischer · University Of South Florida$413,069,911
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$378,749,497
- Gary D Acton · University Of California-Davis$320,373,312
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Lawrence Corey · Fred Hutchinson Cancer Center$319,618,139
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
Research focus
PerformanceBaseAffectNeuropsychological TestsParticipantImpairmentPositioning AttributeAnti-Retroviral AgentsTreatment EffectImpaired CognitionCognitiveNeuropsychologicalRandomizedFutureMemoryHiv InfectionsNeurologicPersonsResponseEvaluationControl GroupsCohortClinical ResearchClinic
Grant awards (23)
A Randomized, Cross-Over Controlled Trial of Dronabinol and Vaporized Cannabis in Neuropathic Low Back Pain$431,084
R01 · FY2019 · DA · contact PI
A Randomized, Cross-Over Controlled Trial of Dronabinol and Vaporized Cannabis in Neuropathic Low Back Pain$612,665
R01 · FY2018 · DA · contact PI
A brief iPad-based screening measure for HIV-associated neurocognitive disorders$526,966
R42 · FY2017 · MH
A brief iPad-based screening measure for HIV-associated neurocognitive disorders$310,116
R42 · FY2017 · MH
A Randomized, Cross-Over Controlled Trial of Dronabinol and Vaporized Cannabis in Neuropathic Low Back Pain$649,606
R01 · FY2016 · DA
A brief iPad-based screening measure for HIV-associated neurocognitive disorders$240,880
R42 · FY2016 · MH
A Randomized, Cross-Over Controlled Trial of Dronabinol and Vaporized Cannabis in Neuropathic Low Back Pain$421,579
R01 · FY2015 · DA
Remediation of HAND: Initial efficacy, real-world relevance, and mechanisms$232,500
R34 · FY2015 · MH · contact PI
Remediation of HAND: Initial efficacy, real-world relevance, and mechanisms$232,500
R34 · FY2014 · MH · contact PI
A brief iPad-based screening measure for HIV-associated neurocognitive disorders$224,953
R41 · FY2013 · MH
Remediation of HAND: Initial efficacy, real-world relevance, and mechanisms$217,650
R34 · FY2013 · MH · contact PI
NeuroAIDS in India$557,736
R01 · FY2011 · MH · contact PI
NeuroAIDS in India$568,839
R01 · FY2010 · MH · contact PI
NeuroAIDS in India$570,296
R01 · FY2009 · MH · contact PI
NeuroAIDS in India$558,494
R01 · FY2008 · MH · contact PI
NeuroAIDS in India$688,417
R01 · FY2007 · MH · contact PI
IMPACT OF REPEATED CANNABIS TREATMENTS ON DRIVING ABILITIES$10,427
M01 · FY2006 · RR · contact PI
IMPACT OF REPEATED CANNABIS TREATMENTS ON DRIVING ABILITIES$51,625
M01 · FY2005 · RR
IMPACT OF REPEATED CANNABIS TREATMENTS ON DRIVING$21,833
M01 · FY2004 · RR
Development of Simulations to Detect Impaired Drivers$165,152
R42 · FY2003 · MH
Development of Simulations to Detect Impaired Drivers$210,549
R42 · FY2002 · MH
Development of Simulations to Detect Impaired Drivers$6,451
R42 · FY2002 · MH
Development of Simulations to Detect Impaired Drivers$192,000
R42 · FY2001 · MH